|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ Hoʻolālā TA1
Puna: PubChem |
Kaʻina: SDAAVDTSSEITTKDLKEKKEVVEEAEN Hui Molekala: C 129H 215N 33O55 Kaumaha Molekala: 3108.3 g/mol Helu CAS: 62304-98-7 PubChem CID: 16130571 Synonyms: Thymalfasin；Zadaxin |
▎ TA1 Imi
He aha ka TA1?
ʻO TA1 kahi polypeptide i haku ʻia me 28 amino acids. Aia maoli ia i loko o ka thymus a he koʻikoʻi koʻikoʻi i ka hoʻomaʻamaʻa ʻana a me ke kaʻina hana ʻokoʻa o nā cell T.
He aha ke kumu noiʻi o TA1?
ʻO TA1 kahi polypeptide bioactive i hoʻokaʻawale ʻia a hoʻomaʻemaʻe ʻia mai ka hakina thymosin 5, aia he 28 amino acids. ʻO ka thymus he ʻāpana koʻikoʻi o ka ʻōnaehana immune, kahi e hana ai i nā mea like ʻole e hoʻoponopono i ka hana immune, a ʻo thymosin kekahi o lākou. Me ka noiʻi hohonu ʻana i nā hana o ka thymus, ua ʻike mālie ka poʻe i nā mea hana i loko o ia mea he waiwai kūpono no ka mālama ʻana i nā maʻi like ʻole.
He aha ke ʻano o ka hana a TA1?
Immunomodulation:
ʻO TA1 kahi mea hoʻololi pane olaola e hiki ai ke hoʻōla i nā ʻāpana like ʻole i ka ʻōnaehana pale. Hoʻoponopono nui ia i ka hana immune ma o ka hoʻonui ʻana i ka ʻokoʻa a me ka oʻo ʻana o nā cell T (Sjogren MH, 2004; Mao L, 2023). Ma ke ʻano kikoʻī, hiki i ka TA1 ke hoʻopili i nā thymocytes ma o ka hoʻoulu ʻana i ko lākou ʻokoʻa a i ʻole ka hoʻololi ʻana iā lākou i mau pūnae T hoʻoikaika.
ʻO ka hana anti-inflammatory:
I ka mālama ʻana i ka maʻi maʻi maʻi COVID-19, hoʻolalelale ʻo TA1 i ka hoʻihoʻi ʻana mai ka pneumonia ma o kāna hana anti-inflammatory. Hiki iā ia ke hōʻemi i ka pane inflammatory, hoʻoikaika i ka hoʻohaʻahaʻa ʻana i nā hōʻailona pili i ka maʻi maʻi COVID-19 e like me ke kuni a me ka luhi, hoʻomaʻamaʻa i ka absorption o exudate, a hoʻolalelale i ka hoʻihoʻi ʻana mai COVID-19 pneumonia (Wang Z, 2023).
Pehea e hoʻoulu ai ʻo Thymalfasin i ka apoptosis o nā ʻiʻo maʻi maʻi i ka mālama ʻana i ka maʻi kanesa?
Hoʻonui i ka hana o nā cell immune:
ʻO Thymalfasin kahi thymopeptide synthetic me ka hana hoʻoikaika kino kiʻekiʻe. Hiki iā ia ke hoʻonui i ka hopena pepehi o nā cell immune ma nā cell tumor, a laila e hoʻoulu i ka apoptosis o nā cell tumor. No ka laʻana, i loko o ka microenvironment tumor, hiki iā Thymalfasin ke hoʻoikaika i ka ʻokoʻa a me ka oʻo ʻana o nā pūnae T a hoʻonui i ka hana o nā pūnae T. Ma ke ʻano he ʻāpana koʻikoʻi o ka ʻōnaehana pale, hiki i nā cell T ke hoʻomaopopo a hoʻouka i nā cell tumor, e hoʻoulu i ka apoptosis o nā cell tumor ma ka hoʻokuʻu ʻana i nā mea cytotoxic a me nā ʻano ʻē aʻe.
Hoʻoponopono i ka pane immune:
Ma ke ʻano he immunopotentiator, hiki iā Thymalfasin ke hoʻoponopono i ka pane ʻana o ka pale a hoʻoulu i ka apoptosis o nā cell tumor. Hiki iā ia ke hoʻonui i ka pane immune Th1. ʻO nā pūnaewele Th1 ka mea huna i nā cytokines e like me IFN-γ, hiki ke hana pololei i nā cell tumor a hoʻoulu i kā lākou apoptosis. Eia hou, hiki iā Thymalfasin ke hoʻoponopono i nā hana o nā pūnaewele immune'ē aʻe, e like me ka hoʻonuiʻana i ka hana o nā pūnaewele NK. Hiki i nā pūnaewele NK ke pepehi pololei i nā pūnaeho maʻi maʻi a hoʻoulu pū i ka apoptosis o nā cell tumor ma o ka huna ʻana i nā cytokines a me nā ʻano hana ʻē aʻe [1].
Hoʻomaikaʻi i ka immunosuppression i ka wā o ka mālama anti-tumor:
I ka wā o ka mālama ʻana i ka maʻi maʻi, ʻike pinepine ka poʻe maʻi i ka immunosuppression, kahi e hoʻopilikia ai i ka maikaʻi o ka mālama ʻana i ka maʻi maʻi. Hiki iā Thymalfasin ke hoʻomaikaʻi i ka immunosuppression i hana ʻia i ka wā o ka mālama anti-tumor, hoʻonui i ka hiki o ka ʻōnaehana pale e hoʻouka i nā cell tumor, a pēlā e hoʻoulu ai i ka apoptosis o nā cell tumor. No ka laʻana, i ka wā o ka chemotherapy a i ʻole radiotherapy, e pōʻino ka ʻōnaehana pale o ka mea maʻi i kekahi ʻano. Hiki i ka Thymalfasin ke hoʻoikaika i ka hoʻihoʻi ʻana a me ka hoʻonui ʻana o nā cell immune, hoʻomaikaʻi i ka hana o ka ʻōnaehana pale, a hoʻonui i ka hopena pepehi ma nā pūnaewele tumor.
Loaʻa i ka Thymosin alpha 1 ka nui o nā hana olaola.
Puna:PubMed [6]
He aha nā mea hoʻohana o Thymalfasin?
ʻO nā maʻi viral:
Ma muli o kona hopena immunomodulatory, hoʻohana pinepine ʻia ʻo TA1 e mālama i nā maʻi viral. No ka laʻana, i ka wā o ka maʻi maʻi COVID-19, ua hōʻike ʻo ia i ka hopena lapaʻau maikaʻi i ka mālama ʻana i ka maʻi maʻi maʻi COVID-19. Hōʻike nā noiʻi hiki i ka TA1 ke pale i ka piʻi ʻana o nā maʻi maʻamau o COVID-19 i ka maʻi pneumonia koʻikoʻi ma o nā ʻano hana hoʻoikaika kino a me nā hana pale anti-inflammatory [2] . ʻO keʻano, no nā maʻi i mālamaʻia me TA1, ua hoʻopōkole nuiʻia ka noho o ka haukapila,ʻo ka hapa o ka hoʻomaha o nā hōʻailona pili i ka maʻi pneumonia (e like me ke kuni a me ka luhi) uaʻoi aku ka kiʻekiʻe ma mua o ka hui hoʻomalu, aʻo kahi o ka exudation inflammatory i hōʻikeʻia e CT ua emi loa ma mua o ka hui hoʻomalu [2] . Eia kekahi, ua hōʻike ʻo multivariate Cox model analysis i ka poʻe maʻi i hoʻohana i ka TA1 a me nā mea maʻi ʻōpio i ka nui o ka wikiwiki o ka hoʻololi ʻana o ka COVID-19 antigens [2] . Ua hoʻonui ʻo Tα1 (ka mea nui o TA1) i ka helu CD4 + T cell i nā poʻe maʻi me ke kākoʻo inhalation oxygen haʻahaʻa ma ka baseline ʻoi aku ka wikiwiki ma mua o ka mālama maʻamau, a hiki ke pāʻani i ka mālama ʻana i nā mea maʻi maʻi me ka hypoxemia a me ka lymphopenia i hoʻokumu ʻia e COVID-19 [3].
Ka mālama ʻana i ka maʻi hepatitis:
Loaʻa i ka TA1 kekahi hopena i ka mālama ʻana i ka maʻi hepatitis. Hiki ke hoʻohanaʻia e like me ka monotherapy no ka maʻi hepa B a iʻole i hui pū me ka interferon α-2b no ka mālamaʻana i ka maʻi hepa C. Ma keʻano kūikawā, uaʻikeʻia kahi noiʻi ma ka mālamaʻana i ka maʻi hepa B, ua loiloiʻia ka maikaʻi o TA1 i nā ho'āʻo hoʻokolohuaʻehā e pili ana i nā maʻi he 195. I loko o kekahi o nā haʻawina, 9 o 17 mau maʻi i mālama ʻia me TA1 i loaʻa i ka maʻi hepatitis B (HBV) DNA clearance i nā mahina ʻeono, ke hoʻohālikelike ʻia me 10 o 16 mau maʻi i mālama ʻia me ka interferon α-2b a me 4 mai 15 mau maʻi i ka hui hoʻomalu mōʻaukala.
Lapaʻau Adjuvant: Hoʻohana nui ʻia ʻo TA1 i ka mālama ʻana i ka maʻi kanesa. No nā poʻe maʻi me ka maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) a me ka maʻi maʻi ate, i ka mālama adjuvant, hiki i ka TA1 ke hoʻomaikaʻi nui i ka helu ola holoʻokoʻa (OS) (Mao L, 2023). No nā poʻe maʻi me ka NSCLC hiki ʻole ke hoʻololi ʻia, hiki i ka TA1 ke hōʻemi nui i ka lymphopenia a me ka maʻi maʻi ma muli o ka radiotherapy a me ka chemotherapy, a aia kahi ʻano o ka hoʻomaikaʻi ʻana i ka OS [4].
Hoʻonui i ka palekana anti-tumor:
Hōʻike nā hōʻike preclinical e hiki i ka TA1 ke hoʻohuli i ka M2 polarization i hoʻoulu ʻia e ka efferocytosis o macrophages ma o ka hoʻoulu ʻana i ke koʻi TLR7/SHIP1, hoʻonui i ka maikaʻi o ka chemotherapy maʻi kanesa, a hoʻonui i ka immunity anti-tumor ma o ka hoʻololi ʻana i 'nā maʻi anuanu' i 'nā maʻi wela' (Mao L, 2023). Eia kekahi, he hopena pale ka TA1 i ka ho'ēmiʻana i ka colitis i hoʻokumuʻia e nā mea hoʻopaneʻe hoʻopalekana immune (ICIs) a hiki ke hoʻonui i ka maikaʻi o nā ICI [4] . ʻO Tα1 ma ke ʻano he lapaʻau kōkua ma hope o ka wehe ʻana i ka maʻi maʻi ʻaʻai hiki ke hoʻomaikaʻi i ka wānana o nā maʻi me ka maʻi maʻi hepatocellular liʻiliʻi. Ma kahi hoʻopaʻa haʻawina retrospective cohort, ua māhele ʻia nā maʻi me ka carcinoma liʻiliʻi hepatocellular i loaʻa i ka ʻoki ʻana i ka ate i ʻelua mau pūʻulu, ʻo ka hui A (resection + Tα1) a me ka hui B (resection wale nō). Ma hope o ka hahai ʻana o ka maʻi ma waena o 47.0 mau mahina, ʻoi aku ka kiʻekiʻe o ka 1-, 3-, a me -makahiki holoʻokoʻa ola a me ka hoʻihoʻi hou ʻole o nā maʻi o ka hui A ma mua o ka poʻe ma ka hui B.5 .
Hoʻihoʻi hou i ka hana immune a me ka hoʻonui ʻana i ke kano:
Hiki ke hoʻohana ʻia ʻo TA1 no ka mālama ʻana i nā mokuʻāina immunocompromised a me nā maʻi maʻi a ma ke ʻano he mea hoʻonui i nā pane kano [4, 6] . Hiki iā ia ke hoʻoponopono i ka ʻōnaehana pale a hoʻonui i ka hana T cell, a loaʻa paha nā pōmaikaʻi lapaʻau no nā maʻi me ka hana ʻino a i ʻole ka maikaʻi ʻole e like me ka maʻi maʻi a me ka maʻi maʻi, ka maʻi kanesa, a me ka pane ʻole o ka lāʻau lapaʻau [4] . Ua hōʻike nā haʻawina i ka sepsis koʻikoʻi, ua hōʻike ʻia ʻo TA1 e hoʻihoʻi i ka hana immune a kōkua i ka hōʻemi ʻana i ka nui o ka make o nā maʻi [4].
Ka pale ʻana i nā maʻi COVID-19 a me nā hoʻopiʻi i nā poʻe maʻi e loaʻa ana i ka dialysis renal:
ʻO ka poʻe maʻi me ka maʻi renal hope loa (ESRD) e loaʻa ana i ka hemodialysis (HD) i manaʻo ʻia he pilikia loa i ka maʻi SARS-CoV2 ma muli o nā kumu e like me ka ʻelemakule, ke kaumaha o ka comorbidity, ka hoʻohana ʻana i ka lāʻau lapaʻau, a me ka pono e kipa pinepine i nā keʻena dialysis. Ua hōʻike ʻia nā haʻawina mua ʻo TA1, ma ke ʻano he mea kōkua i ka lāʻau lapaʻau influenza, hiki ke hoʻoikaika i ka pane ʻana o ka antibody o ka poʻe ʻelemakule (me nā maʻi HD) i ka maʻi maʻi influenza a hōʻemi i nā maʻi influenza. I nā lā mua o ka maʻi maʻi COVID-19, ua manaʻo nā mea noiʻi e hiki i ka lawelawe ʻana i ka TA1 i nā maʻi maʻi HD ke hōʻemi i ka hopena a me ka paʻakikī o nā maʻi COVID-19. Ma Iulai 1, 2022, 254 mau maʻi ESRD / HD mai ʻelima mau kikowaena dialysis ma Kansas City, Missouri i hoʻokomo ʻia i loko o ke aʻo ʻana, kahi o 194 mau maʻi i hoʻokaʻawale ʻia i ka hui A (subcutaneous injection o 1.6mg TA1 ʻelua i ka pule no 8 mau pule) a me ka hui B (hui mana, me ka loaʻa ʻole o TA1) [7].
I ka hopena, ma ke ʻano he polypeptide me nā hana immunomodulatory kūʻokoʻa, ua hōʻike ʻo TA1 i nā noi kūpono i nā ʻano he nui o ka lāʻau lapaʻau. I ka mālama ʻana i nā maʻi maʻi maʻi, he hopena koʻikoʻi ia i nā maʻi e like me ka hepatitis B a me COVID-19. ʻAʻole hiki iā ia ke hoʻolōʻihi wale i ka hōʻoluʻolu o nā hōʻailona a hōʻemi i ka ʻāʻī akā pale pū kekahi i ka piʻi ʻana o ka maʻi a hoʻomaikaʻi i ka helu hoʻihoʻi o nā maʻi. Ma ke ʻano o ka mālama ʻana i ka maʻi tumora, hiki iā ia ke hoʻoulu i ka apoptosis o nā pūnaewele maʻi ma o nā ala he nui, hoʻonui i ka hopena pepehi o nā cell immune ma nā cell tumor, a hoʻomaikaʻi i ke kūlana immunosuppressive, e hōʻike ana i ka hana maikaʻi i ka mālama ʻana i nā maʻi maʻi like ʻole e like me ka maʻi kanesa a me ka maʻi ʻaʻai.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
He kanaka noiʻi ʻo Wang Z me kahi ʻano hoʻonaʻauao like ʻole a me ka ʻike hui like ʻana ma waena o nā ʻoihana he nui. ʻO kā lākou makemake noiʻi e pili ana i nā kahua interdisciplinary e like me Engineering, Spectroscopy, Chemistry, Dentistry, Oral Surgery & Medicine, a me Physics. Ua pili ʻo Wang Z me nā hui koʻikoʻi a me nā kulanui, ʻo ia hoʻi ke University of Chinese Academy of Science (CAS), Yunnan University, Peking University, Hunan Agricultural University, Shanghai Jiao Tong University, a me nā mea ʻē aʻe he nui. Hōʻike kā lākou hana i ka manaʻo ikaika i ka hana hou a me ka hui pū ʻana, ʻoi aku hoʻi i nā wahi e pili ana i ka ʻenehana optoelectronic ʻenehana māmā, nā noi lāʻau lapaʻau, a me nā ʻepekema waiwai holomua. Ma o ka launa pū ʻana me nā ʻoihana e like me ka Jiangsu Provincial Research Center for Light Industrial Optoelectronic Engineering & Technology a me ka Air Force Military Medical University, ua hāʻawi ʻo Wang Z i nā holomua theoretical a me nā noi kūpono i kā lākou ʻoihana loea. Ua helu ʻia ʻo Wang Z ma ka ʻōlelo kuhikuhi [2].
